Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 37 | 2024 | 2921 | 4.040 |
Why?
|
Immunotherapy | 20 | 2024 | 4752 | 1.980 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2024 | 4044 | 1.950 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2021 | 263 | 1.860 |
Why?
|
Oropharyngeal Neoplasms | 9 | 2023 | 492 | 1.570 |
Why?
|
Radiotherapy | 7 | 2023 | 1494 | 1.480 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2022 | 784 | 1.350 |
Why?
|
Neoplasms | 23 | 2024 | 22340 | 1.220 |
Why?
|
Papillomavirus Infections | 9 | 2023 | 1640 | 1.060 |
Why?
|
Combined Modality Therapy | 17 | 2024 | 8529 | 0.950 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9373 | 0.930 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2024 | 328 | 0.840 |
Why?
|
Mouth Neoplasms | 4 | 2022 | 594 | 0.770 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5389 | 0.760 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11868 | 0.740 |
Why?
|
Neoadjuvant Therapy | 8 | 2024 | 2895 | 0.670 |
Why?
|
Neoplasm Metastasis | 11 | 2022 | 4893 | 0.640 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 93 | 0.610 |
Why?
|
Melanoma | 9 | 2021 | 5719 | 0.610 |
Why?
|
Radiation Tolerance | 2 | 2023 | 475 | 0.610 |
Why?
|
Medical Futility | 1 | 2019 | 136 | 0.590 |
Why?
|
Skin Neoplasms | 9 | 2024 | 5849 | 0.590 |
Why?
|
Neck | 1 | 2022 | 733 | 0.580 |
Why?
|
Radiotherapy Dosage | 9 | 2022 | 2865 | 0.580 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 73 | 0.540 |
Why?
|
Head | 1 | 2022 | 925 | 0.540 |
Why?
|
Radiation Oncology | 3 | 2017 | 569 | 0.530 |
Why?
|
Lymphopenia | 1 | 2018 | 297 | 0.510 |
Why?
|
Salivary Gland Neoplasms | 3 | 2020 | 305 | 0.500 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13451 | 0.500 |
Why?
|
Papillomaviridae | 8 | 2022 | 1141 | 0.480 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13648 | 0.470 |
Why?
|
Immunomodulation | 1 | 2019 | 547 | 0.470 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3946 | 0.460 |
Why?
|
Carcinoma, Basal Cell | 3 | 2024 | 566 | 0.450 |
Why?
|
Humans | 117 | 2024 | 765968 | 0.440 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 347 | 0.440 |
Why?
|
Cancer Vaccines | 2 | 2011 | 1044 | 0.430 |
Why?
|
Immunocompromised Host | 1 | 2019 | 866 | 0.430 |
Why?
|
Cookbooks as Topic | 1 | 2012 | 1 | 0.420 |
Why?
|
Retrospective Studies | 33 | 2024 | 81514 | 0.420 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2022 | 1643 | 0.410 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1106 | 0.400 |
Why?
|
Radiation Injuries | 4 | 2021 | 1181 | 0.390 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9249 | 0.390 |
Why?
|
Saliva | 1 | 2017 | 851 | 0.390 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2056 | 0.380 |
Why?
|
Neoplasm Staging | 13 | 2024 | 11206 | 0.370 |
Why?
|
Endoribonucleases | 1 | 2013 | 229 | 0.360 |
Why?
|
Brain Neoplasms | 7 | 2021 | 9071 | 0.360 |
Why?
|
Immunotherapy, Active | 1 | 2010 | 58 | 0.360 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2822 | 0.350 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2020 | 1776 | 0.350 |
Why?
|
Middle Aged | 51 | 2024 | 223009 | 0.350 |
Why?
|
Aged | 44 | 2024 | 171117 | 0.340 |
Why?
|
Carcinoma | 2 | 2023 | 2312 | 0.330 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2022 | 104 | 0.320 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 282 | 0.320 |
Why?
|
Radiosurgery | 4 | 2020 | 1328 | 0.320 |
Why?
|
Palliative Care | 3 | 2020 | 3645 | 0.320 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 496 | 0.300 |
Why?
|
Male | 56 | 2024 | 363698 | 0.300 |
Why?
|
Immunophenotyping | 3 | 2018 | 1866 | 0.290 |
Why?
|
Food | 1 | 2012 | 764 | 0.290 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59489 | 0.290 |
Why?
|
Survival Analysis | 9 | 2021 | 10070 | 0.290 |
Why?
|
Appointments and Schedules | 1 | 2011 | 444 | 0.280 |
Why?
|
Pneumonia | 1 | 2019 | 2157 | 0.280 |
Why?
|
Patient Selection | 2 | 2021 | 4255 | 0.280 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3596 | 0.270 |
Why?
|
Female | 52 | 2024 | 396112 | 0.260 |
Why?
|
Pyrroles | 1 | 2012 | 1119 | 0.250 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1471 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6499 | 0.240 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3211 | 0.240 |
Why?
|
Carcinoma, Renal Cell | 2 | 2018 | 3181 | 0.240 |
Why?
|
Neovascularization, Pathologic | 2 | 2011 | 2631 | 0.230 |
Why?
|
Tumor Burden | 2 | 2021 | 1885 | 0.220 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6942 | 0.220 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12509 | 0.220 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1383 | 0.220 |
Why?
|
Indoles | 1 | 2012 | 1839 | 0.220 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1050 | 0.220 |
Why?
|
Research Design | 1 | 2019 | 6209 | 0.220 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2741 | 0.210 |
Why?
|
Radiation Dosage | 2 | 2022 | 1944 | 0.210 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4642 | 0.210 |
Why?
|
Organs at Risk | 2 | 2022 | 352 | 0.200 |
Why?
|
Pregnancy Proteins | 1 | 2004 | 225 | 0.200 |
Why?
|
Prognosis | 12 | 2024 | 29922 | 0.200 |
Why?
|
Dermatitis | 2 | 2017 | 199 | 0.200 |
Why?
|
Prostatic Neoplasms | 5 | 2020 | 11083 | 0.190 |
Why?
|
Gadolinium | 2 | 2024 | 965 | 0.190 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9525 | 0.180 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 79 | 0.180 |
Why?
|
Immune System | 2 | 2018 | 799 | 0.180 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6832 | 0.180 |
Why?
|
Prostatectomy | 3 | 2014 | 1782 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2024 | 65188 | 0.180 |
Why?
|
Kidney Neoplasms | 2 | 2018 | 4274 | 0.180 |
Why?
|
Parotid Gland | 1 | 2022 | 177 | 0.180 |
Why?
|
Immunologic Factors | 2 | 2021 | 1587 | 0.180 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.180 |
Why?
|
Cisplatin | 3 | 2024 | 1658 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8041 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3356 | 0.170 |
Why?
|
Antibody Formation | 2 | 2016 | 1391 | 0.160 |
Why?
|
Cytokines | 4 | 2019 | 7421 | 0.160 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2021 | 296 | 0.160 |
Why?
|
Adult | 29 | 2024 | 223044 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2021 | 211 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2371 | 0.150 |
Why?
|
Nucleic Acid Denaturation | 1 | 2018 | 111 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20659 | 0.150 |
Why?
|
Anti-Infective Agents, Local | 1 | 2020 | 245 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 378 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 512 | 0.150 |
Why?
|
Survival Rate | 4 | 2018 | 12795 | 0.150 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6547 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5337 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2010 | 3513 | 0.140 |
Why?
|
Radiation Protection | 1 | 2021 | 424 | 0.140 |
Why?
|
Stomatitis | 1 | 2020 | 270 | 0.140 |
Why?
|
Mouth | 1 | 2020 | 381 | 0.140 |
Why?
|
Larynx | 1 | 2022 | 491 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 248 | 0.140 |
Why?
|
Polymerase Chain Reaction | 3 | 2024 | 6069 | 0.140 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 2172 | 0.140 |
Why?
|
Phantoms, Imaging | 2 | 2022 | 2475 | 0.140 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 51 | 0.130 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.130 |
Why?
|
Epirubicin | 1 | 2016 | 82 | 0.130 |
Why?
|
Lymphocyte Count | 1 | 2018 | 790 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 167 | 0.130 |
Why?
|
Gastrointestinal Tract | 1 | 2021 | 834 | 0.120 |
Why?
|
Prospective Studies | 8 | 2021 | 54802 | 0.120 |
Why?
|
Mucositis | 2 | 2019 | 107 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 73 | 0.120 |
Why?
|
Signal Transduction | 3 | 2015 | 23601 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 385 | 0.120 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12056 | 0.120 |
Why?
|
Chemokines | 2 | 2018 | 956 | 0.120 |
Why?
|
Nanoparticles | 2 | 2024 | 1964 | 0.110 |
Why?
|
Ecosystem | 1 | 2018 | 488 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1061 | 0.110 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2024 | 0.110 |
Why?
|
Drug Carriers | 1 | 2018 | 700 | 0.110 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21056 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1915 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39193 | 0.100 |
Why?
|
Lymph Nodes | 3 | 2023 | 3454 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1083 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1315 | 0.100 |
Why?
|
Information Dissemination | 1 | 2021 | 1142 | 0.100 |
Why?
|
SEER Program | 4 | 2020 | 1446 | 0.100 |
Why?
|
Killer Cells, Natural | 2 | 2018 | 2210 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3160 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3537 | 0.100 |
Why?
|
Computational Biology | 1 | 2004 | 3559 | 0.090 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4427 | 0.090 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.090 |
Why?
|
Medical Oncology | 1 | 2023 | 2339 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2887 | 0.090 |
Why?
|
Interferons | 1 | 2015 | 714 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1432 | 0.090 |
Why?
|
Gastrectomy | 1 | 2016 | 694 | 0.090 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1009 | 0.090 |
Why?
|
Transcription, Genetic | 2 | 2004 | 7599 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1555 | 0.090 |
Why?
|
Xerostomia | 1 | 2010 | 94 | 0.090 |
Why?
|
Angiopoietin-1 | 1 | 2010 | 132 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1884 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 183 | 0.090 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 91 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 639 | 0.080 |
Why?
|
Angiopoietin-2 | 1 | 2010 | 187 | 0.080 |
Why?
|
Esophagitis | 1 | 2010 | 163 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1153 | 0.080 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10261 | 0.080 |
Why?
|
Young Adult | 9 | 2021 | 59889 | 0.080 |
Why?
|
Androgen Antagonists | 2 | 2020 | 1411 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1392 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 878 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 3251 | 0.080 |
Why?
|
Cytoskeletal Proteins | 2 | 2005 | 1325 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10383 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2699 | 0.080 |
Why?
|
Colitis | 1 | 2017 | 1239 | 0.070 |
Why?
|
Apoptosis | 1 | 2024 | 9514 | 0.070 |
Why?
|
Gene Library | 1 | 2010 | 1067 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8501 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1761 | 0.070 |
Why?
|
Risk Factors | 6 | 2023 | 74840 | 0.070 |
Why?
|
Carboplatin | 1 | 2010 | 789 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 2010 | 558 | 0.070 |
Why?
|
Cohort Studies | 6 | 2024 | 41649 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1927 | 0.070 |
Why?
|
Animals | 10 | 2022 | 168764 | 0.070 |
Why?
|
Incidental Findings | 1 | 2011 | 697 | 0.070 |
Why?
|
Mucous Membrane | 2 | 2021 | 657 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 605 | 0.070 |
Why?
|
beta Catenin | 3 | 2006 | 1043 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2011 | 964 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40065 | 0.060 |
Why?
|
Glioblastoma | 1 | 2021 | 3459 | 0.060 |
Why?
|
Neutrophils | 1 | 2018 | 3776 | 0.060 |
Why?
|
Developing Countries | 1 | 2017 | 2911 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2023 | 20124 | 0.060 |
Why?
|
Prostate | 1 | 2013 | 1755 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1534 | 0.060 |
Why?
|
Trans-Activators | 2 | 2005 | 2850 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2006 | 414 | 0.060 |
Why?
|
Inflammation | 2 | 2015 | 10850 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5929 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 24282 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 952 | 0.060 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2024 | 202 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3602 | 0.050 |
Why?
|
Umbilical Veins | 1 | 2004 | 421 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.050 |
Why?
|
Philadelphia | 1 | 2023 | 267 | 0.050 |
Why?
|
X-Rays | 1 | 2024 | 310 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2013 | 3222 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2686 | 0.050 |
Why?
|
Capillary Permeability | 1 | 2006 | 768 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11022 | 0.050 |
Why?
|
Logistic Models | 1 | 2017 | 13266 | 0.050 |
Why?
|
Genotype | 2 | 2016 | 13024 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8611 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7478 | 0.050 |
Why?
|
Culture Media | 1 | 2004 | 890 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4850 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 174 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3850 | 0.040 |
Why?
|
Genetic Variation | 1 | 2016 | 6610 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36532 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10808 | 0.040 |
Why?
|
Mice | 5 | 2022 | 81819 | 0.040 |
Why?
|
Endothelium | 1 | 2003 | 767 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4025 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2024 | 2266 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2593 | 0.040 |
Why?
|
Bandages | 1 | 2020 | 269 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 419 | 0.040 |
Why?
|
Mohs Surgery | 1 | 2020 | 219 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 154 | 0.040 |
Why?
|
Algorithms | 2 | 2023 | 14071 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 355 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13632 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 16047 | 0.030 |
Why?
|
Jaw | 1 | 2017 | 94 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 13076 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 898 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 869 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2018 | 393 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 426 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27171 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1617 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7425 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2229 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2020 | 1153 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1272 | 0.030 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 325 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1816 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 449 | 0.030 |
Why?
|
United States | 3 | 2024 | 72903 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 862 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2006 | 3584 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6364 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 517 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 703 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1316 | 0.020 |
Why?
|
HIV Infections | 1 | 2019 | 17533 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2018 | 5881 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2006 | 18973 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2242 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1543 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21480 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1857 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5988 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1946 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4335 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2021 | 8102 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3681 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12437 | 0.020 |
Why?
|
Wound Healing | 1 | 2020 | 2792 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4108 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2048 | 0.020 |
Why?
|
Proteins | 1 | 2004 | 5995 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7202 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2054 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5329 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 916 | 0.020 |
Why?
|
Blotting, Western | 2 | 2006 | 5020 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5501 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3965 | 0.020 |
Why?
|
Histamine Agents | 1 | 2006 | 3 | 0.020 |
Why?
|
Receptors, Histamine | 1 | 2006 | 23 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2207 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6763 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2457 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11888 | 0.020 |
Why?
|
gamma Catenin | 1 | 2005 | 45 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4405 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2942 | 0.020 |
Why?
|
Desmoplakins | 1 | 2005 | 65 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10603 | 0.010 |
Why?
|
Rats | 1 | 2021 | 23707 | 0.010 |
Why?
|
Phosphoserine | 1 | 2005 | 203 | 0.010 |
Why?
|
Base Sequence | 1 | 2016 | 12403 | 0.010 |
Why?
|
Alleles | 1 | 2016 | 6897 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2334 | 0.010 |
Why?
|
Histamine | 1 | 2006 | 497 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11641 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3853 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3655 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13462 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8297 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 2476 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18293 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3529 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26318 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 13039 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2005 | 1495 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Exons | 1 | 2005 | 2391 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15398 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9601 | 0.010 |
Why?
|
Cytoplasm | 1 | 2003 | 1500 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2453 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4873 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2006 | 2878 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2003 | 3089 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 2627 | 0.010 |
Why?
|
Actins | 1 | 2003 | 2056 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4475 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6493 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8278 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5743 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30198 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9296 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15543 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9443 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 14448 | 0.000 |
Why?
|
Adolescent | 1 | 2015 | 88835 | 0.000 |
Why?
|
Lung | 1 | 2003 | 10033 | 0.000 |
Why?
|